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1010 The Journal of Thoracic and CardObjective: Malignant pleural mesothelioma is notoriously refractory to aggressive
multimodality therapy. Epidermal growth factor receptor expression has been ob-
served on malignant pleural mesothelioma cells. Epidermal growth factor receptor–
mediated signaling promotes tumorigenesis and metastasis of cancer cells. The
purpose of this study is to evaluate the ability of the epidermal growth factor
receptor tyrosine kinase inhibitor PD153035 to abrogate the expression of prome-
tastasis phenotypes in malignant pleural mesothelioma cells in vitro.
Methods: Epidermal growth factor receptor expression of malignant pleural me-
sothelioma cells and primary normal cells was quantitated by means of flow
cytometry. PD153035-mediated growth inhibition was determined by means of
1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan and clonogenic assays. Cell
motility and invasion of extracellular matrix was evaluated with in vitro wound-
healing and Matrigel invasion assays, respectively. Vascular epidermal growth
factor levels in conditioned media were measured by using enzyme-linked immu-
nosorbent assay.
Results: Epidermal growth factor receptor expression was detected on all 6 cultured
malignant pleural mesothelioma cells, with 4 of 6 having normal receptor expres-
sion and 2 of 6 overexpressing the receptor. PD153035 suppressed cell motility and
cell invasion through a Matrigel membrane, regardless of the baseline epidermal
growth factor receptor expression. Decreased vascular epidermal growth factor
production and significant inhibition of growth only occurred in malignant pleural
mesothelioma cells that overexpress epidermal growth factor receptor.
Conclusions: Epidermal growth factor receptor tyrosine kinase inhibitor PD153035
significantly inhibited motility and invasion in malignant pleural mesothelioma cells
in vitro, regardless of their epidermal growth factor receptor expression levels.
Inhibition of epidermal growth factor receptor–dependent signaling might be a
useful strategy to diminish malignant pleural mesothelioma recurrence after aggres-
sive cytoreductive surgery.
Malignant pleural mesothelioma (MPM) is a rare but deadly disease char-acterized by unrelenting locoregional invasion and encasement of con-tiguous intrathoracic organs leading to death. Aggressive multimodality
therapy involving radical extrapleural pneumonectomy coupled with postresection
chemotherapy-radiotherapy, although effective in a small subset of patients with
MPM, has substantial treatment-related complications.1 In conjunction with ongo-
ing clinical efforts to design more effective treatments for MPM, considerable
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TSattention has been focused on the development of targeted
molecular therapy for this disease.
The development of a malignant tumor from its micro-
scopic focus, similar to the formation of metastasis, is a
multistep process. This process involves the acquisition of
multiple cellular phenotypes, such as proliferation, resis-
tance to apoptosis, motility, and invasion through extracel-
lular ground substance, as well as the ability to stimulate
angiogenesis (collectively termed prometastasis pheno-
types). Substantial experimental evidence has indicated the
important role of members of the epidermal growth factor
receptor (EGFR) superfamily (particularly ErbB1/EGFR or
erbB2/HER2/neu) in promoting malignant transformation
and metastasis.2 Furthermore, overexpression of EGFR or
HER2/neu has been observed to correlate with locally ad-
vanced disease, distant metastasis, resistance to chemora-
diation and diminished survival in patients with breast, lung,
Figure 1. Flow cytometric analysis of EGFR expression
cells (normal skin fibroblast, normal human skin epi
epithelial cells [NHBE]) in vitro. The EGFR-overexpress
of EGFR expression is indicated by the EGFR–fluoresce
and Methods” section. Representative data of 3 indepesophageal, and ovarian carcinomas.3,4 Stimulation of
The Journal of ThoracicEGFR by its natural ligands, transforming growth factor 
or epidermal growth factor, through either an autocrine or
paracrine mechanism results in activation of its intrinsic
tyrosine kinase activity and receptor autophosphorylation.
Activated EGFR, through recruitment of multiple adaptor
molecules (eg, SOS and Grb2), as well as functional proteins
(eg, PI3K p110 subunit), initiates parallel cascades of down-
stream intracellular signaling pathways, namely the Ras/Raf/
MAPK (ERK1/2), Rac/Rho, PI3K/AKT, and STAT pathways.
The biologic responses from such a diverse intracellular sig-
naling include cell proliferation, survival, motility, invasion,
adhesion, and angiogenesis.2
Selective inhibition of the EGFR tyrosine kinase activity
with pharmacologic antagonists or blocking monoclonal
antibodies in cancer cells expressing high levels of EGFR
through abrogation of receptor-mediated transduction of
signals to multiple intracellular pathways effectively sup-
panel of 6 cultured MPM cells and 3 primary normal
l keratinocyte [NHEK], and normal human bronchial
431 cells serve as the positive control. The magnitude
thiocyanate MFI index, as described in the “Materials




endepresses tumor cell growth and enhances their sensitivity to
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that showed profound biologic effects of the anti-EGFR
therapy have frequently been performed in cultured cancer
cell lines expressing extremely high levels of EGFR, such as
H431 or DiFi cells.6 However, little attention has been
placed on the effect of EGFR antagonists on cancer cells
with normal levels of EGFR. Additionally, there has been
little investigation into EGFR antagonist influence on cel-
lular phenotypes other than proliferation and survival, such
as cell motility or cell invasion, which are equally important
in promoting tumorigenesis.
The primary objective of this study is to evaluate the
effect of the pharmacologic EGFR antagonist PD153035, a
well-described EGFR-selective tyrosine kinase inhibitor
(TKI),7 on expression of prometastasis phenotypes in cul-
tured MPM cells that express different levels of EGFR. The
other objective is to determine whether there is a correlation
between the levels of baseline EGFR expression and the
biologic response to EGFR TKI by using multiple cellular
phenotypes as end points.
Materials and Methods
Cells and Reagents
Cultured MPM cells and EGFR-positive H431 cells were main-
tained in RPMI medium supplemented with 10% fetal calf serum
(FCS), glutamine (1 mmol/L), and antibiotics (streptomycin,
Figure 2. Growth-inhibitory effect of PD153035 on cultured MPM
cells expressing different levels of EGFR. Cells seeded in 96-well
microtiter plates were continuously treated with varying concen-
trations of PD153035 for 96 hours. Cell viability was determined by
using the MTT assay and expressed as a percentage of untreated
control cells. PD153035 IC50 values of each cell line derived from
the respective dose-response curves are shown in Table 1. Data
are expressed as means  SEM of 4 independent experiments.100 mg/mL; penicillin, 100 U/mL). Normal human skin keratin-
1012 The Journal of Thoracic and Cardiovascular Surgery ● Maocytes, dermal fibroblasts, and bronchial epithelial cells were
purchased from Clonetics (Cambrex Int, Walkerville, Md) and
cultured as per the instructions of the vendor. PD153035 was
obtained from Tocris Cookson, Inc (Ellisville, Mo), dissolved in
dimethyl sulfoxide as 10 mmol/L stocks, and stored at 20°C.
Flow Cytometric Analysis of EGFR Expression
The surface expression of EGFR on cultured MPM cells or pri-
Figure 3. Inhibition of clonogenic activity of cultured MPM cells
by PD153035 (PD). Cells were seeded in 6-well tissue culture
plates and continuously treated with PD153035 for 10 days,
whereas individual colonies were formed from individual seeded
cells. The clonogenicity of control or PD153035-treated cells was
recorded by means of digital photography (A) as representative
assays of H2595, H2373, and H2052 are shown here and quanti-
tated by means of image analysis (B), as described in the “Ma-
terials and Methods” section. Data are expressed as means 
SEM of 4 independent experiments (#P  .0003 to <.0001 for
1000 nmol/L PD153035-treated vs control cells; *P< .0001 for 2500
nmol/L PD153035-treated vs control cells).mary normal cells was determined by means of indirect immuno-
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The density of EGFR expression on the cell surface was indicated
by the EGFR mean fluorescence intensity (MFI) index (the ratio of
the MFI of EGFR staining and the MFI of the IgG isotype control).
Cell Proliferation and Clonogenic Assays
Cultured MPM cells were seeded in 96-well plates (3000-5000
cells per well) and subsequently treated with PD153035 (250-
5000 nmol/L) for 96 hours, with a replacement of fresh media
(with or without PD153035) at 48 hours. Cell viability of
control and PD153035-treated cells was quantitated with
1-(4,5-dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT; Sig-
ma-Aldrich, St Louis, Mo). The PD153035 IC50 values (con-
Figure 4. Cell-cycle analysis of representative MPM cells after
48 hours of exposure to PD153025 (PD; 2500 nmol/L), as deter-
mined by means of propidium iodide staining and flow cytometry.
Representative data of 3 independent experiments with similar
results are shown here.
Figure 5. Inhibition of cell motility by PD153035 in cultured MPM
cells, as evaluated by using the in vitro wound healing assay. Cell
motility, as evidenced by narrowing of the wound edge, is shown.
Fresh wound is shown as a baseline control of the assay. Rep-
resentative digital photomicrographs are shown here.
The Journal of Thoraciccentrations of PD153035 that mediated 50% inhibition of cell
proliferation) were extrapolated from the respective dose-re-
sponse curves. Cultured MPM cells were seeded at 300 to 1000
cells per well in 6-well plates and continuously exposed to
PD153035 (1000, 2500, and 5000 nmol/L) for 3 days. Cells
were further cultured in fresh PD153035-free complete media
for 7 more days. Cell colonies were then fixed with 1% para-
formaldehyde and stained with Diff-Quick (Dade Behring Inc,
Newark, Del). The colonies were photographed with a digital
camera, and colony density was quantitated by means of image
analysis with Adobe Photo-Shop 5.0 (Adobe Inc, San Jose,
Calif).
Cell Motility Assay
Cell motility was evaluated by using the in vitro wound-healing
assay, as previously described.9 MPM cells were seeded in 12-well
plates to obtain 90% confluence. After an overnight incubation,
wounds were made by scratching the cell monolayer with a sterile
plastic pipette tip. Cells were then treated with PD153035 (1000,
2500, or 5000 nmol/L) for 24 hours. Movement of cells from
wound edges into the wounds was indicative of cell motility. Cells
were fixed with 1% paraformaldehyde, and the magnitude of
wound healing was recorded with digital microphotography.
Matrigel Invasion Assay
Cell migration and invasion through the Matrigel membrane was
quantitated by using the commercially available cell-invasion kit
(Chemicon Int, Temecula, Calif). MPM cells treated with
PD153035 (1000, 2500, or 5000 nmol/L) in FCS-free media were
seeded in the invasion chambers and stimulated to migrate and
Figure 6. Inhibition of cell invasion-migration through the extra-
cellular matrix Matrigel by PD153035 in cultured MPM cells. The
magnitude of cell invasion through the Matrigel membrane was
recorded by means of digital photomicrography. Representative
pictures are shown here.invade the Matrigel-containing filter by using serum-containing
and Cardiovascular Surgery ● Volume 129, Number 5 1013
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fully traversed the Matrigel layer were stained with the cell stain
provided in the kit and photographed with a digital camera.
Vascular Epidermal Growth Factor Assay
Levels of vascular epidermal growth factor (VEGF) in conditioned
media of MPM cells (baseline control cells or after PD153035
treatment [1000, 2500, or 5000 nmol/L] for 48 hours) were mea-
sured by means of enzyme-linked immunosorbent assay (R&D
Biosystems, Minneapolis, Minn). VEGF levels in the conditioned
media were normalized for total cellular protein and expressed as
picograms per milliliter per milligram of cellular protein. Defer-
oxamine (100 mol/L) was used to simulate the hypoxic
condition.
Data Presentation and Statistical Analysis
Data are presented as means  SEM of at least 4 independent
experiments with similar results. The 2-tail Student t test or anal-
ysis of variance with the Bonferroni post test for pairwise com-
parisons was used as indicated for statistical analysis (GraphPad
software, San Diego, Calif).
Results
EGFR Expression on Cultured MPM Cells
All MPM cell lines expressed EGFR, as determined by means
of immunofluorescence staining and flow cytometry. High
levels of EGFR were detected on H513 and H2595 cells with
MFI indexes of 43 and 30, respectively compared with an MFI
index of 60 in H431-positive control cells. The other 4 cultured
MPM cells had EGFR levels (MFI indexes ranging from 9 to
13) that were similar to those of primary normal cells of
ectodermal and mesodermal origin (Figure 1).
Growth-inhibitory Effect of PD153035 on MPM Cells
Continuous exposure of MPM cells to PD153035 resulted in
a significant dose-dependent inhibition of cell proliferation
only in cell lines expressing high levels of EGFR (H513 and
H2595), with PD153035 IC50 values ranging from 1800 to
2900 nmol/L. Inhibition of cell proliferation was noticeable










H513 42 1915 153 40%*
H2595 30 2882 527 60%*
H211 12 3119 193 42%*
H2373 12 3517 189 45%*
H28 10 5000 10%
H2052 10 5000 0
EGFR, Epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; IC5
 .0001. †P  .0025. ‡P  .025.only at a high concentration of PD153035 at 5000 nmol/L
1014 The Journal of Thoracic and Cardiovascular Surgery ● Ma(H211 and H2373) or absent (H28 and H2052) in cell lines
with normal EGFR (Figure 2). The profound growth-
inhibitory effect of PD153035 in cells expressing high lev-
els of EGFR was duplicated with the clonogenic assay
(Figure 3). Substantial suppression of the clonogenicity was
observed in 2 high-EGFR cell lines, H513 and H2595 (at
PD153035 concentrations as low as 1000 nmol/L), as well
as in 2 cell lines expressing normal EGFR levels, H211 and
H2373 (at PD153035 concentrations of 2500 nmol/L).
Interestingly, PD153035 at 5000 nmol/L profoundly abro-
gated the clonogenic activity of the remaining 2 cultured
MPM cell lines with normal EGFR expression levels (H28
and H2052) that were not at all growth inhibited by
PD153035 when evaluated by using the MTT cell-prolifer-
ation assay. In cells that were growth inhibited by
PD153035 (eg, H513 or H2595), but not in those that were
refractory to PD153035 effect (H2595 or H28), there was a
significant accumulation of cells in the G0/G1 phase of the
cell cycle (with concomitant reduction of cells in the S and
G2/M phases), which is indicative of arrest of cell-cycle
progression at the G1/S checkpoint (Figure 4). There was no
apoptosis of PD153035-treated cells (2500 or 5000 nmol/L
for up to 5 days), as determined by means of TUNEL-based
ApoBrdU assay (data not shown).
Inhibition of Cell Motility and Invasion of Matrigel
Membrane In Vitro by PD153035
PD153035 treatment mediated significant suppression of
cell motility of all cultured MPM cells in vitro, as evaluated
by using the wound-healing assay (Figure 5). Similarly,
PD153035 treatment also strongly inhibited cellular
invasion-migration through the Matrigel membrane in re-
sponse to the chemoattractant effect of FCS (Figure 6). The
magnitudes of PD153035-mediated suppression of cell mo-
tility or cell invasion-migration through the Matrigel mem-
brane versus control levels were semiquantitatively scored
from 1 (minimal inhibition) to 5 (90% inhibition) and


















, inhsummarized in Table 1. In contrast to its growth-inhibitory
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expression status, there appeared to be little correlation
between the levels of EGFR expression and the magnitudes
of inhibition of cell motility and cell invasion through the in
vitro extracellular matrix Matrigel.
Inhibition of VEGF Production at Baseline and After
Deferoxamine-simulated Hypoxic Condition by
PD153035
The levels of VEGF in conditioned media of cultured MPM
cells under baseline and after simulated hypoxic condition
with or without PD153035 exposure were measured by
means of enzyme-linked immunosorbent assay and normal-
ized for the total cellular protein of the cell pellets. High
levels of VEGF were noted in the conditioned media of
H513 and H2595 (high EGFR) and H28 (normal EGFR)
cells compared with lower levels of VEGF in other cultured
MPM cells (H211, H2373, and H2052 cells; Figure 7, A).
PD153035 treatment significantly suppressed VEGF pro-
duction by those cells with high baseline levels (30%-50%
reduction from baseline control levels, P  .025 to .0001;
Figure 7, A). On the other hand, PD153035 treatment did
not alter VEGF production in cell lines expressing normal
EGFR with lower baseline VEGF levels. Hypoxia is a
powerful stimulus for upregulation of VEGF production in
normal physiologic and pathologic conditions. Deferox-
amine treatment was used to simulate the hypoxic condition
in representative MPM cell lines (high-EGFR H513 cells
and normal-EGFR H2052 and H211 cells). Chemically
stimulated hypoxia caused 2.2-fold (H513 and H211) to
3-fold (H2052) increases of VEGF levels in the conditioned
media. PD153035 treatment during the hypoxic condition
differentially suppressed hypoxia-induced VEGF upregula-
tion only in high-EGFR H513 cells but not in normal-EGFR
H2052 or H211 cells (Figure 7, B).
Discussion
EGFR-targeted therapy was conceived on the basis of the
observation that dysregulated EGFR-mediated signal trans-
duction plays an important role in carcinogenesis, tumor
progression, and a significant proportion of cancers of dif-
ferent histology and expresses increased levels of EGFR
when compared with normal cells.4 Moreover, it is believed
that cancer cells expressing high EGFR levels depend on
this receptor for proliferation-survival and thus are more
susceptible to EGRF blockade. Differential expression of
EGFR in tumor cells versus nontumor normal tissues can
provide an exploitable therapeutic window in cancers
known to overexpress EGFR. Preclinical studies of anti-
EGFR strategies showed promising and at times spectacular
results of significant induction of apoptosis (in vitro and in
vivo) and regression of established tumor xenografts.10 Fur-
ther preclinical evaluation of the anticancer effect of selec-
tive EGFR TKI has shown mixed results. Some investiga-
The Journal of Thoracictors reported correlation between the levels of EGFR
expression7 and response to EGFR blockade, whereas oth-
ers showed no relationship between EGFR levels and EGFR
TKI–mediated inhibition of cell proliferation.11 The in vitro
cell proliferation assay is frequently performed when eval-
uating the growth-inhibitory property of drugs because it
can be readily used in high throughput screenings. Our
experiments, using the standard monolayer proliferation
assay, indicated that cell lines expressing high levels of
EGFR (H513 and H2595) were significantly growth inhib-
ited, whereas other MPM cells with normal EGFR levels
were much less sensitive or even refractory to the EGFR
TKI PD153035. However, the clonogenic assay indicated
Figure 7. The effect of PD153035 (PD) on VEGF production and
secretion into the conditioned media of cultured MPM cells at
baseline (#P  .0001 [H513], P  .0025 [H2595], and P  .025 [H28]
for cells treated with 200 nmol/L PD153035 vs control cells; A) and
under simulated hypoxic condition (deferoxamine) in represen-
tative H513, H2052, and H211 cells (*P  .0008 [H513], P  .004
[H211], and P  .002 [H2052], hypoxia vs control; **P  .0008,
hypoxia vs PD153035/hypoxia; B). Data are expressed as means
SEM of 4 independent experiments.that 5000 nmol/L PD153035 effectively suppressed forma-
and Cardiovascular Surgery ● Volume 129, Number 5 1015
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though PD153035 is EGFR selective at nanomolar concen-
trations, it is unclear whether PD153035 at 5000 nmol/L
would exert an inhibitory effect on other tyrosine kinases.
Moreover, pharmacokinetic analysis indicated that the drug
concentration achievable at the maximally tolerated dose of
oral EGFR TKI ZD 1839 (Iressa; AstraZeneca, Wilmington,
Del) was approximately 2000 nmol/L. The in vitro biologic
effects of higher concentrations of EGFR TKI, such as
PD153035, as seen in our study or reported by other authors
using ZD 1839, might be irrelevant.12
Cell proliferation is only one component of the molecular-
cellular cascade of tumor development and metastasis. Cell
motility and invasion through extracellular matrix are other
facets of malignant phenotypes. The current cellular paradigm
of metastasis formation suggests that it is a multistep process:
detachment from tumor mass, migration through the extracel-
lular matrix, lymphatic-hematologic dissemination, exiting
from the vasculature, formation of metastatic deposits, and
recruitment of angiogenesis for macroscopic tumor develop-
ment. The ability of cancer cells to migrate through the artifi-
cial extracellular matrix membrane Matrigel frequently corre-
lates with their invasiveness in vivo.13 In contrast to its ability
to inhibit cell proliferation only in cells expressing increased
EGFR levels at a reasonable drug concentration, PD153035
treatment strongly suppresses cell motility and cell migration-
invasion through Matrigel membrane in vitro of all cultured
MPM cells, regardless of their baseline EGFR expression at
PD153035 concentrations of 1000 to 5000 nmol/L. The short
duration of the assay (24 hours) precludes the possibility that
such inhibition of cell kinesis is related to the antiproliferation
effect of PD153035 in susceptible cell lines (H513 and
H2595). Even though we did not evaluate the effect of EGFR
blockade on production of matrix metalloproteinases (MMPs)
in this study, our previous works,8,14 as well as those of
others,15 have demonstrated significant inhibition of the secre-
tion of MMP-9/MMP-2, as well as the reduction of MMP-2/
MMP-9, protease activity in the conditioned media of cultured
cancer cells treated with anti-EGFR therapy.
EGFR-mediated signaling through the PI3K/AKT path-
way, particularly in the hypoxic condition, has been shown
to transcriptionally regulate VEGF gene expression.16 It is
interesting to see higher levels of baseline VEGF in condi-
tioned media of H2595 and H513 cells than in those of
MPM cells with normal EGFR levels, such as H2052,
H2373, and H211 cells. Significant inhibition of baseline
VEGF production was observed in 2 high-EGFR cells
(H513 and H2595) and only in 1 of 4 normal-EGFR MPM
cells (H28). It is clear from our study that EGFR antago-
nists, such as the TKI PD153035, have a limited role in
suppressing VEGF production in cultured MPM cells, par-
ticularly in those not overexpressing this proto-oncoprotein.
Further works are in progress to evaluate the effect of EGFR
1016 The Journal of Thoracic and Cardiovascular Surgery ● Mainhibition on downstream signaling pathways in cell lines
expressing different levels of this receptor to demonstrate
the potential relationship between distinct signal transduc-
tion pathways and prometastatic phenotypes. Early-phase
clinical trials suggest that EGFR TKIs have demonstrable
clinical activity against a wide variety of solid tumors,
including cancers of the lung, esophagus, ovary, and head
and neck.17,18 Unfortunately, 2 large phase III trials failed to
show the beneficial effects of combining EGFR TKI with
cytotoxic chemotherapeutic agents, in contrast to preclinical
studies.4 Ongoing investigations are underway to elucidate
the molecular basis of cellular resistance to this treatment
strategy: the importance of EGFR–phosphorylated EGFR in
tumors and the presence of constitutive activation of the
AKT pathway among others.19,20 On the other hand, dra-
matic responses to EGFR antagonists have been observed in
a small subset of patients with lung cancer, particularly
female nonsmokers with adenocarcinoma (bronchoalveolar
carcinoma).21-23 Genetic analysis has identified somatic mu-
tations in the tyrosine kinase domain of the EGFR gene
(such as the missense mutation Leu858¡Arg858 [L858R]
or the 18-base pair inframe deletion [delL747-P753insS]).
EGFR mutants have been shown to exhibit enhanced ty-
rosine kinase activity in response to epidermal growth factor
and increased sensitivity to EGFR TKIs.19-21 It is unlikely
that the cultured MPM cells used in this study have such a
mutation of the EGFR gene because they are not very
sensitive to the growth-inhibitory effect of PD153035, and
these unique somatic mutations have only been identified in
primary non–small cell lung cancers but not in other cancers
of different histology.19 It is hard to expect compounds such
as EGFR TKIs, which exert mainly cytostatic and not cy-
tocidal activity, to produce objective response in patients
with heavy tumor burdens. It is, however, more reasonable
to develop EGFR TKI therapy as chemoprevention or as a
long-term adjuvant after ablative therapy that reduces tumor
burden to a microscopic state. It is in this state that EGFR-
targeted therapy might have the best chance to be beneficial.
We thank Mr Arnold Mixon and Mr Shawn Farid (Flow Cy-
tometry Core Facility, Surgery Branch, NCI/NIH) for their expert
assistance and Mr Don White for statistical analysis.
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Discussion
Dr David R. Jones (Charlottesville, Va). I enjoyed your talk very
much. I have one quick question for you. Did you look at any
specific proteins that might be affecting motility? In other words,
why is there decreased motility, and what pathways do you think
might be involved?
Dr Cole. That is a very good question. We are starting to look
at those specific proteins right now. In fact, on the basis of data that
we did not present here but that were just recently concluded, I
have a sneaking suspicion that motility is going to be affected
through AKT. We have used a specific AKT blocker in our same
wound-healing assay, and the results of using that blocker are very
dramatic.
Dr Yolonda Colson (Boston, Mass). Have you considered
using the EGFR antibodies in this assay as well?
Dr Cole. I think that is something that we would like to
explore. In terms of a clinical model, the EGFR antibodies, as you
know, have to be delivered intravenously, and we were thinking of
something more easily deliverable to the patient in terms of an oral
medication, which led us to the TKIs.
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